Date: Sunday, November 8, 2015
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA) and the incidence are known as about 0.5 to 1 %. To evaluate clinical characteristics and incidence of Japanese patients with ReA induced by intravesical BCG therapy (iBCG) for bladder cancer.
Methods: The clinical symptoms, laboratory, and imaging findings of Japanese patients who received iBCG (n=453 (182 and 271 in Kochi University Hospital (KUH) and Kurashiki Medical Center (KMC), respectively)) for bladder cancer from March 1997 to April 2015 (for 19 years) were retrospectively assessed. Especially, the patients with ReA and conjunctivitis/uveitis were examined. All data are presented as mean ± SD.
Results: Of the patients received iBCG (age 71±10 and 69±11; male/female 134/48 and 215/56 in KUH and KMC, respectively), 50/182 (27%) and 35/271 (13%), 51/182 (28%) and 48/271 (18%), and 78/182 (43%) and 73/271 (27%) in KUH and KMC presented fever, hematuria and painful urination, respectively. ReA was revealed in 4/182 (2.2%) and 3/271 (1.1%), uveitis in 3/182 (1.6%) and 1/271 (0.4%), and conjunctivitis in 15/182 (8.2%) and 14/271 (5.2%) in KUH and KMC, respectively. As the total evaluation, ReA was revealed in 7/453 (1.5%). Moreover, most patients with ReA also had hepatic dysfuntion. All ReA were developed after 3-times of iBCG. Clinical, ultrasound and FDG-PET/CT findings of ReA induced by iBCG showed asymmetric polyarthritis/polyenthesitis pattern in shoulder, sternoclavicular joints, spinous process, sacroiliac joints, ischial tuberosity, hip, knee and ankle. Laboratory examinations showed high CRP (>10mg/dl), 25% HLA-B27 positivity (in 1 of 4 cases), 50% HLA-B51 positivity (in 2 of 4 cases). All ReA patients were improved by treatments with prednisolone and isoniazid.
Conclusion: The incidence of ReA induced by iBCG in Japanese population was 1.5 % and it might be almost equal or more than the incidence, 0.5 to 1 %, in the Western countries from previous reports. Positive HLA-B27 was revealed in 25% of ReA patients as background in our study, suggesting lower frequency than 51 to 55% in the Western countries. Therefore, besides HLA phenotype, a cross reaction between a mycobacterium epitope and an antigen of joint cartilage might be suggested in the pathogenesis of ReA induced by iBCG in Japan.
To cite this abstract in AMA style:Nishikawa H, Taniguchi Y, Karashima T, Aita T, Nishiyama S, Yoshinaga Y, Kumon Y, Shimamura Y, Inoue K, Horino T, Shuin T, Terada Y. Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-japanese-patients-with-reactive-arthritis-induced-by-intravesical-bcg-therapy-for-bladder-cancer-a-19-years-two-center-retrospective-study/. Accessed October 26, 2021.
« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-japanese-patients-with-reactive-arthritis-induced-by-intravesical-bcg-therapy-for-bladder-cancer-a-19-years-two-center-retrospective-study/